Trial Profile
A retrospective study to evaluate efficacy of intravitreal aflibercept as primary treatment for myopic choroidal neovascularisation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Oct 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 15 Oct 2016 New trial record